IDYA — IDEAYA Biosciences, Inc.
Is IDYA overbought or oversold? Here is the current MarketMoodz read.
IDEAYA Biosciences, Inc. (IDYA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $30.36. The rating moved from Oversold to Strong Oversold on November 16, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$30.36
- Last changeMoved from Oversold to Strong Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
IDEAYA Biosciences, Inc. (IDYA) is an oncology-focused small-cap with scientific differentiation in DNA damage response and synthetic lethality approaches. The company’s value is driven largely by clinical-program binary events, partnership optionality, and the ability to fund development without excessive dilution. Financially, operating losses and limited revenue create dependency on capital markets or collaborations. Near-term outlook hinges on upcoming trial readouts and any partnership or financing announcements; positive outcomes could generate meaningful upside while negative clinical or cash‑related developments would likely produce steep declines. Market sentiment in the immediate window is cautiously risk-on, which may modestly support biotech names, but IDYA remains sensitive to idiosyncratic clinical and funding news.
Key factors
- Pipeline focus on targeted oncology (DNA damage response / synthetic lethality) provides meaningful binary clinical and partnership catalysts.
- Historical ability to attract partnerships and licensing interest increases optionality for non-dilutive funding or milestone-driven upside.
- Typical small-cap biotech financial profile: limited product revenue, negative operating cash flow and dependence on capital markets or collaborations to fund development.
- Upcoming clinical readouts and regulatory milestones (early- and mid-stage trials) that can materially re-rate the equity in either direction.
- Overall market tone in the last several hours is cautiously risk-on, which can help biotech risk assets modestly but not insulate against idiosyncratic clinical news.
Risks
- Clinical trial failures or disappointing efficacy/safety readouts in key studies, which would likely trigger sharp share-price weakness.
- Short cash runway or the need for equity issuance leading to dilution if partnership or non-dilutive financing is not secured.
- Regulatory risk and uncertain reimbursement environment for novel oncology agents, affecting commercial prospects and pricing power.
- Competitive rival programs (other DDR/PARP/synthetic lethality approaches) and potential for larger pharma to crowd the space or acquire competitors.
- Low trading liquidity and high volatility typical of small-cap biotech stocks, amplifying downside on negative news.
- Macro/market risk (rate and risk‑sentiment shifts) that can rapidly reduce appetite for speculative biotech names.
See today's live rating, score and targets
Members see the live hourly rating for IDYA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.